Mont-Saint-Guibert, Belgium, –The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces the appointment of Dr. Gaëtane Metz as Chief Operating Officer in view of accelerating the industrialization process and preparing the commercialization of its lead product C-Cure®.
Dr. Metz brings to the Company extensive experience in industry, where she has built experience in Research & Development, medical affairs and operational excellence including automation to increase productivity, management of inspection, integration of production, reorganization and simplification of processes, and transfer products from R&D to commercial manufacturing.
Prior to joining C3BS, Dr. Metz held the position of Managing Director of the Life Sciences, Energy and Industry Division at Altran Europe. Dr. Metz has also held senior and management positions at CVO CyberConseil, and GlaxoSmithKline Biologicals (GSK) where she worked for 11 years. Her work included all aspects and stages of project management, driving the various departments to collaborate and integrate with one another in order to speed up processes and increase efficiency.
Dr. Metz holds a PhD in Bioengineering/Biomedical from the Free University of Brussels (ULB).
Dr. Gaëtane Metz, COO, said: “Cardio3 BioSciences’ pipeline holds great therapeutic potential for significant, currently unmet medical needs. I am pleased and excited to have the opportunity to join the Company and lead operations to help the transition of C-Cure® from late clinical development to a commercial product.”
Dr Christian Homsy, CEO of Cardio3 BioSciences, commented: “I am delighted to have Dr Metz join the management team and share her process and industrialization expertise as we prepare for the commercialization of our lead product candidate, C-Cure. Dr Metz’s expertise in process development and experience in automation and industrialization will be instrumental in building the systems that will provide the foundations for the launch of C-Cure®.”
